RECURSION PHARMACEUTICALS, INC. — Form 8-K
Filed November 2, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Recursion reported positive Phase 2 data for REC-4881 (MEK1/2 inhibitor) in familial adenomatous polyposis: 87% of patients achieved polyp burden reductions (47% median) after 12 weeks; 85% remained below baseline 12 weeks off-treatment; 92% achieved upper GI reductions with 2 patients ≥98% reduction; 6 of 8 patients with larger polyps (>5mm) showed reductions. Sanofi optioned the first development candidate from their collaboration (potential first-in-class dual-target immunology molecule), triggering $10M milestone payment; Recursion eligible for >$300M additional milestones plus double-digit royalties. Company extended cash runway into 2029 following $187.2M October 2026 financing; 2026 cash operating expense guidance reiterated <$375M; appointed Fred Hassan as Board Chair effective October 31, 2026.
Why this rating
Strong clinical proof-of-concept in lead program (REC-4881) significantly de-risks FAP opportunity (~$15B market, ~50K patients); Sanofi milestone validates platform repeatability and provides near-term revenue; Hassan appointment strengthens pharma credentials. Relative to $2B market cap, these achievements materially validate strategy but remain mid-stage clinical, with registrational trial expected H2 2027.
See more from November 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.